Palvella Therapeutics (PVLA) – Research Analysts’ Weekly Ratings Updates

Palvella Therapeutics (NASDAQ: PVLA) recently received a number of ratings updates from brokerages and research firms:

• 5/21/2026 – Palvella Therapeutics had its “overweight” rating reaffirmed by Stephens. They now have a $220.00 price target on the stock.
• 5/21/2026 – Palvella Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $240.00 price target on the stock.
• 5/12/2026 – Palvella Therapeutics is now covered by Stephens. They set an “overweight” rating and a $220.00 price target on the stock.
• 5/12/2026 – Palvella Therapeutics is now covered by Stephens. They set an “overweight” rating and a $220.00 price target on the stock.
• 4/11/2026 – Palvella Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.50% of the stock is currently owned by company insiders.

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.